Nina Dusilkova

Vestec, ST, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

Journal: Blood cancer journal
Published: April 14, 2022

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.

Journal: Cells
Published: December 15, 2021

Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry.

Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry.

Journal: Folia biologica
Published: June 09, 2020

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.

Journal: International journal of molecular sciences
Published: August 31, 2017

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.

Journal: Blood cancer journal
Published: July 22, 2017

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.

Journal: Oncotarget
Published: March 29, 2017

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.

Journal: Blood cancer journal
Published: September 24, 2016

Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas.

Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas.

Journal: International journal of hematology
Published: March 03, 2015

Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum.

Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum.

Journal: BMC cancer
Published: October 24, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026